KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Change in Acquisitions & Divestments (2018 - 2025)

Vir Biotechnology's Change in Acquisitions & Divestments history spans 8 years, with the latest figure at $342.9 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments rose 13.88% year-over-year to $342.9 million; the TTM value through Dec 2025 reached $1.2 billion, down 30.91%, while the annual FY2025 figure was $1.2 billion, 30.91% down from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $342.9 million at Vir Biotechnology, up from $305.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $715.7 million in Q4 2023 and bottomed at $79.9 million in Q3 2021.
  • The 5-year median for Change in Acquisitions & Divestments is $305.2 million (2025), against an average of $340.9 million.
  • The largest annual shift saw Change in Acquisitions & Divestments skyrocketed 427.69% in 2023 before it tumbled 57.93% in 2024.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $79.9 million in 2021, then surged by 233.92% to $266.7 million in 2022, then surged by 168.39% to $715.7 million in 2023, then plummeted by 57.93% to $301.1 million in 2024, then rose by 13.88% to $342.9 million in 2025.
  • Per Business Quant, the three most recent readings for VIR's Change in Acquisitions & Divestments are $342.9 million (Q4 2025), $305.2 million (Q3 2025), and $251.3 million (Q2 2025).